文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

既往结直肠肿瘤患者结直肠癌化学预防:系统综述与网络Meta分析

Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2016-12-05

该系统综述与网络Meta分析纳入15项随机对照试验(共12234例既往结直肠肿瘤患者),比较10种化学预防策略。非阿司匹林非甾体抗炎药预防进展期异时性肿瘤效果最佳(OR 0.37,95%可信区间0.24至0.53),低剂量阿司匹林安全性最好(OR 0.78,95%可信区间0.43至1.38)。

要点

  • 非阿司匹林非甾体抗炎药预防进展期异时性肿瘤效果最佳(OR 0.37,95%可信区间0.24至0.53)。
  • 低剂量阿司匹林在化学预防药物中安全性排名最高(OR 0.78,95%可信区间0.43至1.38)。
  • 高剂量阿司匹林疗效与低剂量相当(OR 1.12,95%可信区间0.59至2.10),但安全性较差。

核心结论

  • 在既往结直肠肿瘤患者中,非阿司匹林非甾体抗炎药是预防进展期异时性肿瘤最有效的药物,而低剂量阿司匹林具有最有利的风险获益比。

研究设计与样本

  • 系统综述与网络Meta分析,检索Medline、Embase、Web of Science(自建库至2015年10月15日)及临床试验注册库。
  • 纳入15项随机对照试验,共12234例既往结直肠肿瘤成人患者,比较10种化学预防策略。
  • 主要疗效结局为进展期异时性肿瘤风险,安全性结局为严重不良事件,采用贝叶斯网络Meta分析及SUCRA概率进行相对排名,证据质量采用GRADE标准评价。

主要发现

  • 与安慰剂相比,非阿司匹林非甾体抗炎药预防进展期异时性肿瘤排名最佳(OR 0.37,95%可信区间0.24至0.53;SUCRA=0.98;高质量证据)。
  • 低剂量阿司匹林预防进展期异时性肿瘤的OR为0.71(95%可信区间0.41至1.23;SUCRA=0.67;低质量证据)。
  • 低剂量阿司匹林在化学预防药物中安全性排名最高(OR 0.78,95%可信区间0.43至1.38;SUCRA=0.84)。
  • 非阿司匹林非甾体抗炎药安全性排名较低(OR 1.23,95%可信区间0.95至1.64;SUCRA=0.26)。
  • 高剂量阿司匹林疗效与低剂量阿司匹林相当(OR 1.12,95%可信区间0.59至2.10;SUCRA=0.58),但安全性较差(SUCRA=0.51)。

关键数值与推荐

  • 非阿司匹林非甾体抗炎药预防进展期异时性肿瘤:OR 0.37(95%可信区间0.24至0.53),SUCRA=0.98,高质量证据。
  • 低剂量阿司匹林预防进展期异时性肿瘤:OR 0.71(95%可信区间0.41至1.23),SUCRA=0.67,低质量证据。
  • 低剂量阿司匹林安全性:OR 0.78(95%可信区间0.43至1.38),SUCRA=0.84。
  • 非阿司匹林非甾体抗炎药安全性:OR 1.23(95%可信区间0.95至1.64),SUCRA=0.26。
  • 高剂量阿司匹林疗效:OR 1.12(95%可信区间0.59至2.10),SUCRA=0.58;安全性SUCRA=0.51。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the comparative efficacy and safety of candidate agents (low and high dose aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), calcium, vitamin D, folic acid, alone or in combination) for prevention of advanced metachronous neoplasia (that is, occurring at different times after resection of initial neoplasia) in individuals with previous colorectal neoplasia, through a systematic review and network meta-analysis. DATA SOURCES: Medline, Embase, Web of Science, from inception to 15 October 2015; clinical trial registries. STUDY SELECTION: Randomized controlled trials in adults with previous colorectal neoplasia, treated with candidate chemoprevention agents, and compared with placebo or another candidate agent. Primary efficacy outcome was risk of advanced metachronous neoplasia; safety outcome was serious adverse events. DATA EXTRACTION: Two investigators identified studies and abstracted data. A Bayesian network meta-analysis was performed and relative ranking of agents was assessed with surface under the cumulative ranking (SUCRA) probabilities (ranging from 1, indicating that the treatment has a high likelihood to be best, to 0, indicating the treatment has a high likelihood to be worst). Quality of evidence was appraised with GRADE criteria. RESULTS: 15 randomized controlled trials (12 234 patients) comparing 10 different strategies were included. Compared with placebo, non-aspirin NSAIDs were ranked best for preventing advanced metachronous neoplasia (odds ratio 0.37, 95% credible interval 0.24 to 0.53; SUCRA=0.98; high quality evidence), followed by low-dose aspirin (0.71, 0.41 to 1.23; SUCRA=0.67; low quality evidence). Low dose aspirin, however, was ranked the safest among chemoprevention agents (0.78, 0.43 to 1.38; SUCRA=0.84), whereas non-aspirin NSAIDs (1.23, 0.95 to 1.64; SUCRA=0.26) were ranked low for safety. High dose aspirin was comparable with low dose aspirin in efficacy (1.12, 0.59 to 2.10; SUCRA=0.58) but had an inferior safety profile (SUCRA=0.51). Efficacy of agents for reducing metachronous colorectal cancer could not be estimated. CONCLUSIONS: Among individuals with previous colorectal neoplasia, non-aspirin NSAIDs are the most effective agents for the prevention of advanced metachronous neoplasia, whereas low dose aspirin has the most favorable risk:benefit profile. REGISTRATION: PROSPERO (CRD42015029598).

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ. 2016. PMID: 27919915. doi:10.1136/bmj.i6188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。